MYLeukaemia

MISO Chip

This company develops microfluidic tumor-on-a-chip platforms for biopharmaceutical firms and academic researchers to conduct preclinical ex vivo drug testing on human tissue models.

Organo-ID

The company develops 3D organoid models and drug response tests for cancer patients and pharmaceutical researchers to improve personalised medicine and treatment efficacy.

Pear Bio

The company develops a precision medicine platform using microfluidic chips and computer vision to predict cancer treatment efficacy for oncologists and pharmaceutical researchers.

Xilis

Xilis develops miniature patient-derived tumour models for precision oncology and drug discovery, serving clinicians and pharmaceutical companies.

VitrofluidiX

VitrofluidiX develops an integrated organ-on-a-chip platform for pharmaceutical companies and research institutions to conduct predictive human biology testing without animal models.

PreComb

This company develops a precision oncology platform using patient-derived microtumour models and automated analysis to predict drug responses for biopharmaceutical firms and clinical institutions.

LEUKO

This company develops a non-invasive device for monitoring white blood cell levels at home for cancer patients undergoing chemotherapy.

Known Medicine

This company develops a platform using 3D cell culture and artificial intelligence to predict drug responses for oncologists and biopharmaceutical developers.